Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05622682 · ClinicalTrials.gov registry record
Vaccine Immune Recovery After Leukemia
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 89
- Enrollment target
NCT05622682: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT05622682 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05622682 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.
Primary Outcome
Infections include clinical and/or microbiologically confirmed infections as well as patient-reported infections during follow-up. All unique infections for a given subject will be captured and included in the final infection rate per person time estimate. The total number of unique infections identified within the first year after completing chemotherapy will be reported as a rate per patient-year. Patients will be censored at time of loss to follow-up, relapse, or death.
Interventions
- OTHER Observational only: Serology and flow cytometry for ALL cohort participants
- OTHER Observational only: Infection rates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2025-11-30 |
What the finished NCT05622682 record still lists
NCT05622682 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Observational only: Serology and flow cytometry for ALL cohort participants is the first listed.
NCT05622682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05622682 about?
NCT05622682 is a clinical study titled "Vaccine Immune Recovery After Leukemia". This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating i...
What is the current status of trial NCT05622682?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2022-09-28. Estimated completion is 2025-11-30.
What interventions are being tested in trial NCT05622682?
The interventions under investigation include: Observational only: Serology and flow cytometry for ALL cohort participants (OTHER), Observational only: Infection rates (OTHER).
Who is sponsoring clinical trial NCT05622682?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI